ClinicalTrials.gg
Active, not recruitingNCT05979311VOGUEUpdated Oct 14, 2026

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

A Phase 3 interventional study of Dolutegravir and Lamivudine in HIV and HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 64 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Updated Oct 14, 2026Study completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
12th of 55
463 · median 126
Started
2024
with 2 others
Phase 3
21 of 55
2 open now
Registered
48th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 12th largest by enrollment, is one of 3 that started in 2024, is one of 21 in phase 3, and was the 48th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

This study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) in HIV-1 infected adult participants who have not previously received antiretroviral therapy.

03

Conditions studied

  • HIV
  • HIV Infections

Keywords

  • Antiretroviral-naïve
  • Bictegravir
  • Dolutegravir
  • Emtricitabine
  • Human immunodeficiency virus 1 (HIV-1)
  • Lamivudine
  • Virologic suppression
  • Tenofovir alafenamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with age >=18 years (or older, if required by local regulations) at the time of obtaining .
  • An individual participant is eligible to participate if they are not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at Screening and a negative urine hCG test at Enrollment) and not lactating.
  • Antiretroviral-naïve (no prior therapy with any antiretroviral agent following a diagnosis of -1 infection) person living with HIV.
  • Participant (or participant's legally acceptable representative [LAR]) is capable of giving written informed consent.
  • Eligible participants or their LAR must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrollment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
  • Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.

Exclusion criteria

Exclusion Criteria:

  • Individuals who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of a current Centers for Disease Control and Prevention (CDC) Stage 3 disease; with the exception of cutaneous Kaposi's sarcoma not requiring systemic therapy, and \<200 cells per cubic millimeter (neither is exclusionary).
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates study participation.
  • Ongoing or pancreatitis.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the Investigator and the Medical Monitor for inclusion of the participant prior to enrollment.
  • Participants with severe hepatic impairment (Class C) as determined by classification.
  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • (ALT) >=5 times the (ULN) or ALT >=3*ULN and >=1.5*ULN (with >35% direct bilirubin).
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment.
  • Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • Signs and symptoms which, in the opinion of the Investigator, are suggestive of active Coronavirus disease 2019 (COVID-19) (example fever, cough) infection within 14 days prior to enrollment.
  • Evidence of virus (HBV) infection based on the results of central lab testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B surface antibody (HBsAb) and HBV Deoxyribonucleic Acid (DNA) as follows:

    a. Participants positive for HBsAg are excluded; b. Participants negative for HBsAb and negative for HBsAg but positive for hepatitis B core antibody (HBcAb) may be excluded based on the following consideration: i. Exclude if HBV DNA is detected [either \<Lower Limit of Quantification (LLoQ), >Upper Limit of Quantification (ULoQ) OR numerical value (i.e., between LLoQ and ULoQ)] ii. Not excluded if HBV DNA is negative, not detected

  • Participants with virus (HCV) co-infection at Screening are eligible only if:

    i. liver enzymes meet entry criteria; and ii. HCV disease is not anticipated to require on-study treatment with any agent(s) that have potential adverse drug-drug interactions (DDIs) with the study interventions; and iii. HCV disease has undergone appropriate work-up and is not advanced and will not require treatment prior to the primary endpoint or later visit. Additional information on participants with HCV co-infection at screening should include results from any liver , Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.

iv. In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility

  1. Fib-4 score >3.25 is exclusionary;
  2. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation.

Fibrosis 4 score Formula:

(Age * Aspartate aminotransferase [AST]) / ( * (square root of ALT)

  • Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded. Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor. Participants who completed treatment at least 7 days prior to Screening are eligible.
  • Presence of any major resistance-associated mutations as defined by the International Antiviral Society-United States of America (IAS-USA) resistance guidelines to DTG, 3TC, BIC, FTC or TAF in the Screening result.
  • Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to first dose of study treatment.
  • Treatment with any of the following agents within 28 days of Screening:

    i. radiation therapy; ii. cytotoxic chemotherapeutic agents; iii. tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid, INH); iv. immunomodulators that alter immune responses such as chronic systemic , interleukins, or interferons.

  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any agent with documented activity against HIV-1 in vitro within 28 days of first dose of study treatment. Treatment withacyclovir/valacyclovir is permitted.
  • Participants receiving any protocol-defined prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in an interventional clinical trial.
  • Participant has estimated creatine clearance \<30 milliliter per minute (mL/min) per 1.73 square meter using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method.
  • Participants known or suspected to have acquired HIV-1 concurrent with use of Pre-exposure prophylaxis (PrEP) or Post-exposure prophylaxis (PEP) must be discussed with the Medical Monitor prior to enrollment.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
  • Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participant is currently participating in, or anticipates being selected for, any other interventional study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    DTG/3TC

    Participants will receive FDC of DTG/3TC once daily until Week 96.

    Drug: Dolutegravir · Drug: Lamivudine

  • Active comparator
    BIC/FTC/TAF

    Participants will receive BIC/FTC/TAF once daily until Week 96.

    Drug: Bictegravir · Drug: Emtricitabine · Drug: Tenofovir alafenamide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with plasma HIV- Ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) as per snapshot algorithm at Week 48

    Time frame: Week 48

Secondary outcomes

  1. Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Weeks 24 and 96

    Time frame: Weeks 24 and 96

  2. Percentage of participants with HIV-RNA greater than or equal to (>=)50 c/mL as per snapshot algorithm at Weeks 24, 48, and 96

    Time frame: Weeks 24, 48 and 96

  3. Change from Baseline in HIV-1 RNA at Weeks 24, 48 and 96

    Time frame: Baseline (Day 1) and Weeks 24, 48 and 96

  4. Change from Baseline in Cluster of differentiation 4 positive (CD4+) cell count at Weeks 24, 48 and 96

    Time frame: Baseline (Day 1) and Weeks 24, 48 and 96

  5. Change from Baseline in CD4/Cluster of differentiation 8 (CD8) at Weeks 24, 48 and 96

    Time frame: Baseline (Day 1) and Weeks 24, 48 and 96

  6. Number of Participants With HIV-1 Disease Progression

    Time frame: Weeks 24, 48 and 96

  7. Time to virologic suppression (HIV-1 RNA <50 c/mL) from Baseline

    Time frame: Baseline (Day 1) and Up to Week 96

  8. Number of participants with confirmed virologic withdrawal (CVW)

    Time frame: Up to Week 96

  9. Number of Participants with treatment-emergent resistance

    Time frame: Up to week 96

  10. Change from Baseline in Renal Biomarkers- estimated glomerular filtration rate at Weeks 48 and 96

    Time frame: Baseline (Day 1), Weeks 48 and 96

  11. Change from Baseline in Renal Biomarkers- urinary protein/creatinine at Weeks 48 and 96

    Time frame: Baseline (Day 1), Weeks 48 and 96

  12. Change from Baseline in renal biomarker- Serum Cystatin C at Weeks 48 and 96 (Milligrams per liter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  13. Change from Baseline in renal biomarker- Serum Retinol Binding Protein (RBP) at Weeks 48 and 96 (Milligrams per deciliter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  14. Change from Baseline in renal biomarker- Serum Beta-2 Microglobulin (B2M) at Weeks 48 and 96 (Micrograms per milliliter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  15. Change from Baseline in bone biomarkers- Serum Bone Specific Alkaline Phosphatase, Serum Procollagen type 1 N- Propeptide, Serum Type I Collagen C-Telopeptides and Serum Osteocalcin at Weeks 48 and 96 (Micrograms per Liter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  16. Change from Baseline in bone biomarkers- Serum Vitamin D at Weeks 48 and 96 (Nanomoles per Liter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  17. Change from Baseline (Week 4) in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction status Questionnaire (HIVTSQs) at Weeks 12, 24, 48 and 96 (Scores on a scale)

    The HIVTSQ status version (HIVTSQs) is assessing participants' satisfaction with their current treatment with a Total score ranging from 0 to 60. Higher scores indicate a greater level of satisfaction with HIV treatment. Baseline is defined as measurement value at Week 4.

    Time frame: Baseline (Week 4) and Weeks 12, 24, 48 and 96

  18. Change from Baseline (Week 4) in Individual Item Scores Using HIVTSQs at Weeks12, 24, 48 and 96 (Scores on a scale)

    Individual items scores range from 0 to 6 (0=very dissatisfied, 6=very satisfied). Baseline is defined as measurement value at Week 4.

    Time frame: Baseline (Week 4) and Weeks 12, 24, 48 and 96

  19. Change from Baseline (Week 4) in Domains Scores Using HIVTSQs at Weeks 12, 24, 48 and 96 (Scores on a scale)

    There are two domain scores of General Satisfaction/Clinical and Lifestyle/Ease subscales; each comprised of 5 items with possible scores of 0 to 30. The higher the score, the greater the satisfaction within the subscale. Baseline is defined as measurement value at Week 4.

    Time frame: Baseline (Week 4) and Weeks 12, 24, 48 and 96

  20. Change from Baseline in bothersome symptoms using the Symptom Distress Module at Weeks 4, 12, 24, 48 and 96 (Score on a scale)

    The Symptom Distress Module (SDM) is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom bother score is based on the score for each symptom present ranging from 1 (it does not bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score).

    Time frame: Baseline (Day 1) and Weeks 4, 12, 24, 48 and 96

  21. Absolute values for waist and hip circumference (Centimeters)

    Time frame: Up to Week 96

  22. Absolute values for waist to hip ratio and waist to height ratio (Ratio)

    Time frame: Up to Week 96

  23. Absolute values for Body weight (Kilogram)

    Time frame: Up to Week 96

  24. Absolute values for systolic and diastolic blood pressure (millimeters of mercury)

    Time frame: Up to Week 96

  25. Change from Baseline in Body Mass Index (kilogram per square meter)

    Time frame: Baseline (Day 1) and Up to Week 96

  26. Change from Baseline in body weight greater than (>) 5 percentage (%) at Weeks 24, 48 and 96

    Time frame: Baseline (Day 1) and Weeks 24, 48 and 96

  27. Change from Baseline in total and regional (trunk and extremities) fat assessed by Dual-energy X-ray absorptiometry (DXA) at Weeks 48 and 96

    Time frame: Baseline (Day 1), Weeks 48 and 96

  28. Change from Baseline in total and regional (trunk and extremities) fat-free mass assessed by DXA Weeks 48 and 96

    Time frame: Baseline (Day 1), Weeks 48 and 96

  29. Change from Baseline in lumbar and hip bone mineral density (BMD) assessed by DXA at Weeks 48 and 96

    Time frame: Baseline (Day 1), Weeks 48 and 96

  30. Change from Baseline in trabecular bone score (TBS) assessed by DXA at Weeks 48 and 96

    Trabecular bone score (TBS) is a lumbar spine dual-energy absorptiometry texture index, which provides information on microarchitecture skeletal quality partially independent of BMD.

    Time frame: Baseline (Day 1), Weeks 48 and 96

  31. Change from Baseline in fasting glucose (Millimoles per Liter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  32. Change from Baseline in insulin (Microunits per millilliter)

    Time frame: Baseline (Day 1), Weeks 48 and 96

  33. Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 48 and Week 96

    Time frame: Baseline (Day 1), Week 48 and Week 96

  34. Change from Baseline in Hemoglobin A1c [HbA1c] at Week 48 and Week 96 (Percentage of HbA1c)

    Time frame: Baseline (Day 1), Week 48 and Week 96

  35. Change from Baseline in plasma lipids (total, high-density lipoprotein [HDL], and low-density lipoprotein [LDL] cholesterol, triglycerides) (Millimoles per Liter) at Week 48 and Week 96

    Time frame: Baseline (Day 1), Week 48 and Week 96

  36. Change from Baseline in QDiabetes Score at Week 48 and Week 96 (Scores on a scale)

    QDiabetes score defines the risk (percentage) of developing type 2 Diabetes in the next ten years. The score ranges from 0-100.

    Time frame: Baseline (Day 1), Weeks 48 and 96

  37. Change from Baseline in Fibrosis 4 (FIB-4) Score at Week 48 and Week 96 (Scores on a scale)

    A value of FIB-4 scores below 1.30 is considered as low risk for advanced fibrosis; value of FIB-4 over 2.67 is considered as high risk for advanced fibrosis; and FIB-4 values between 1.30 and 2.67 are considered as intermediate risk of advanced fibrosis.

    Time frame: Baseline (Day 1), Weeks 48 and 96

  38. Number of participants with metabolic syndrome at Weeks 48 and 96

    Time frame: Weeks 48 and 96

  39. Change from Baseline in Framingham cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale)

    Coronary heart disease (CHD) risk at 10 years in percent (%) can be calculated with the help of the Framingham Risk Score. Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more.

    Time frame: Baseline (Day 1), Weeks 48 and 96

  40. Change from Baseline in Data collection on Adverse events of anti-HIV Drugs (DAD) cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale)

    Coronary heart disease (CHD) risk at 5 years in percent can be calculated with the help of the DAD Risk Score. The 5-year risk of CHD is classified as low (\<1%), moderate (1 to 5%), high (5 to 10%), or very high (\>10%).

    Time frame: Baseline (Day 1), Weeks 48 and 96

  41. Changes from Baseline in Systolic and diastolic blood pressure at Weeks 48 and 96 millimeters of mercury (mmHg)

    Time frame: Baseline (Day 1), Weeks 48 and 96

07

Study locations

64 sites
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1425AWK, Argentina
  • GSK Investigational Site
    Córdoba, X5000JJS, Argentina
  • GSK Investigational Site
    Brussels, Brussels Capital 1000, Belgium
  • GSK Investigational Site
    Antwerp, 2000, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Lyon, 31059, France
  • GSK Investigational Site
    Montpellier, 34090, France
  • GSK Investigational Site
    Nice, 06202, France
  • GSK Investigational Site
    Nîmes, 30029, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75970, France
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60590, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Cologne, 50668, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Athens, 106 76, Greece
  • GSK Investigational Site
    Athens, 11 527, Greece
  • GSK Investigational Site
    Thessaloniki, 54635, Greece
  • GSK Investigational Site
    Dublin, 7, Ireland
  • GSK Investigational Site
    Dublin, D09 V2N0, Ireland
  • GSK Investigational Site
    Haifa, 31096, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Bari, 70124, Italy
  • GSK Investigational Site
    Bergamo, 24127, Italy
  • GSK Investigational Site
    Padova, 35128, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Sassari, 07100, Italy
  • GSK Investigational Site
    Aichi, 460-0001, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Tokyo, 108-8639, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Mérida, 97070, Mexico
  • GSK Investigational Site
    Bydgoszcz, 85-030, Poland
  • GSK Investigational Site
    Lodz, 91-347, Poland
  • GSK Investigational Site
    Wroclaw, 50-136, Poland
  • GSK Investigational Site
    Aveiro, 3814-501, Portugal
  • GSK Investigational Site
    Porto, 4099-001, Portugal
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Elche Alicante, 03203, Spain
  • GSK Investigational Site
    La Laguna-Tenerife, 35010, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Marbella, 29603, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07120, Spain
  • GSK Investigational Site
    Palma de Mallorca, 7198, Spain
  • GSK Investigational Site
    Valencia, 46014, Spain
  • GSK Investigational Site
    Stockholm, SE-141 86, Sweden
  • GSK Investigational Site
    Basel, Canton of Basel-City 4031, Switzerland
  • GSK Investigational Site
    Zurich, 8005, Switzerland
  • GSK Investigational Site
    Glasgow, Lanarkshire G12 OYN, United Kingdom
  • GSK Investigational Site
    London, E9 6SR, United Kingdom
  • GSK Investigational Site
    London, SE5 8AF, United Kingdom
  • GSK Investigational Site
    London, W1D 6AQ, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
08

References and documents

Publications

  • Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, Paredes Ceballos O, Stocker H, Mendez Vazquez MJ, Gatanaga H, Metallidis S, Elbirt D, Whitlock G, Mateo Gonzalez JI, Mohammed P, Wang K, Grove R, Wang R, Jewell A, Sutton K, Elliot E, Moodley R, Borsi R, Jones B, Kisare M, Budnik P, van Wyk J; VOGUE Study Group; VOGUE Study Group. VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. Open Forum Infect Dis. 2026 Jul 28;13(8):ofag471. doi: 10.1093/ofid/ofag471. eCollection 2026 Aug. PubMed 42597905 ↗

Individual participant data

Plan to share: Yes — ViiV will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2026, 25 months.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Mar 2027, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 7, 2023
StartActual
Feb 21, 2024
Primary completionActual
Apr 15, 2026
CompletionEst.
Mar 26, 2027was Feb 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Belgium, 1 Germany, 1 Switzerland, 1 United Kingdom)
  • GSK Investigational Site · Brussels, Belgium
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Basel, Switzerland
  • GSK Investigational Site · Glasgow, United Kingdom
Show 4 removed
  • GSK Investigational Site · Brussels, Belgium
  • GSK Investigational Site · Frankfurt, Germany
  • GSK Investigational Site · Basel, Switzerland
  • GSK Investigational Site · Glasgow, United Kingdom
Oct 14, 2026
Study completion
Feb 23, 2027→Mar 26, 2027
Oct 14, 2026
Enrollment
307→463
Oct 14, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42597905 ↗
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42597905 ↗
    4 sites added, 4 sites removed
    Show 4 added (1 Belgium, 1 Germany, 1 Switzerland, 1 United Kingdom)
    • GSK Investigational Site · Brussels, Belgium
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Basel, Switzerland
    • GSK Investigational Site · Glasgow, United Kingdom
    Show 4 removed
    • GSK Investigational Site · Brussels, Belgium
    • GSK Investigational Site · Frankfurt, Germany
    • GSK Investigational Site · Basel, Switzerland
    • GSK Investigational Site · Glasgow, United Kingdom
    Study completion Feb 23, 2027→Mar 26, 2027
    Enrollment 307→463
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05979311
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Feb 21, 2024
Primary completion
Apr 15, 2026
Completion
Mar 26, 2027 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion